Integrated BioFoundry DBTL: BioFoundry (ultrahigh-speed microbial breeding) DBTL: Elementary technology utilization Scale-up process development In-house product development Intestinal microbiome model
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
A startup has developed a painless, simple test using tears to detect cancer early and monitor for recurrence. Using cutting-edge technology originating from Kobe University, it enables highly sensitive detection of extracellular vesicles, allowing testing in everyday settings like homes or pharmacies.
A startup developing a tooth regeneration drug that enables the regeneration of missing teeth in congenital anodontia by utilizing neutralizing antibodies that suppress molecules inhibiting tooth germ growth.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.